Analysts Raise Alnylam Targets After Rival's Trial Fails
Analysts lifted price targets for Alnylam Pharmaceuticals after a rival's failed clinical trial strengthened the company's dominant position in a lucrative heart disease market.
Morgan Stanley and Raymond James raised their price targets on Alnylam Pharmaceuticals this week. The adjustments cap a period of significant analyst activity driven by a major competitive shift in the cardiomyopathy treatment space.
Morgan Stanley increased its valuation to $400 from $370 on July 10 while maintaining an Equal Weight rating. The day prior, Raymond James raised its target to $468 from $420 and reiterated an Outperform rating. Earlier in the month, on June 29, H.C. Wainwright lowered its target to $470 from $510 but kept a Buy rating on the stock.
The divergence in these price targets underscores a complex narrative for investors to navigate. The primary catalyst for the recent upward adjustments was the failure of a Phase 3 ATTR-CM trial conducted by Ionis Pharmaceuticals. Raymond James highlighted that this clinical miss substantially strengthens Alnylam's competitive moat in the space.
By removing a key rival to Alnylam's TTR silencer franchise, the Ionis failure effectively improves the pricing outlook for Alnylam's portfolio. Still, the market is treating the development with nuance. Raymond James pointed out that the trial results may raise risk for Alnylam's own next-generation nucresiran trial in patients receiving background tafamidis.
H.C. Wainwright's reduced target reflects this underlying near-term uncertainty. The firm explicitly cut its near-term estimates for Amvuttra, Alnylam's commercial product, suggesting some short-term revenue pressures. However, the long-term investment thesis remains intact for the firm, which continues to estimate that Alnylam's TTR franchise will grow to over $20 billion in annual revenues by 2040.
Alnylam discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference across the United States, Europe, and international markets. The recent analyst coverage reveals a biopharmaceutical company currently trading on a tension between near-term estimate cuts and a dramatically improved long-term competitive landscape.
